Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
niraparib (zejula) (3 trials)
Breast Neoplasms (Phase 3)
Carcinoma (Phase 3)
Carcinoma, Ovarian Epithelial (Phase 3)
Hypersensitivity (Phase 3)
Ovarian Neoplasms (Phase 3)
Trials (3 total)
Trial APIs (1 total)